
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


X4 Pharmaceuticals Inc (XFOR)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: XFOR (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $41.08
1 Year Target Price $41.08
3 | Strong Buy |
2 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -10.07% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 35.82M USD | Price to earnings Ratio - | 1Y Target Price 41.08 |
Price to earnings Ratio - | 1Y Target Price 41.08 | ||
Volume (30-day avg) 5 | Beta 0.6 | 52 Weeks Range 1.35 - 26.82 | Updated Date 08/15/2025 |
52 Weeks Range 1.35 - 26.82 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -15.14 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-07-31 | When - | Estimate -0.0883 | Actual -3.47 |
Profitability
Profit Margin - | Operating Margin (TTM) -1329.55% |
Management Effectiveness
Return on Assets (TTM) -41.92% | Return on Equity (TTM) -207.22% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 50895240 | Price to Sales(TTM) 1.09 |
Enterprise Value 50895240 | Price to Sales(TTM) 1.09 | ||
Enterprise Value to Revenue 1.55 | Enterprise Value to EBITDA 1.1 | Shares Outstanding 11408400 | Shares Floating 8603156 |
Shares Outstanding 11408400 | Shares Floating 8603156 | ||
Percent Insiders 1.29 | Percent Institutions 25.89 |
Upturn AI SWOT
X4 Pharmaceuticals Inc

Company Overview
History and Background
X4 Pharmaceuticals, founded in 2014, is a biopharmaceutical company focused on discovering and developing novel therapeutics to improve immune cell trafficking to treat diseases resulting from immune dysfunction. The company went public in 2017.
Core Business Areas
- Drug Development: Focuses on the development of therapies for rare diseases by restoring normal immune cell trafficking.
Leadership and Structure
Paula Ragan, Ph.D., is the President and CEO. The company has a typical biotech structure with R&D, clinical development, and commercial functions.
Top Products and Market Share
Key Offerings
- Mavorixafor: Mavorixafor is X4 Pharmaceutical's lead drug candidate, an oral, once-daily CXCR4 antagonist. Mavorixafor is being studied for WHIM syndrome, a rare primary immunodeficiency disease. The market for rare immunodeficiencies is relatively untapped. Competitors depend on indication and might include companies developing gene therapies or other targeted therapies for similar conditions.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and regulatory hurdles. Companies focus on specific disease areas or therapeutic platforms.
Positioning
X4 Pharmaceuticals is positioned as a company specializing in rare diseases, targeting unmet medical needs through its CXCR4 antagonist platform.
Total Addressable Market (TAM)
The TAM for therapies addressing rare immunodeficiency diseases is estimated to be in the billions of dollars, driven by high unmet need and potential for orphan drug designation. X4 is positioned to capture a share of this TAM with mavorixafor.
Upturn SWOT Analysis
Strengths
- Novel CXCR4 antagonist platform
- Lead product with orphan drug potential
- Experienced management team
- Focus on rare diseases with unmet needs
Weaknesses
- Reliance on single product candidate
- High cash burn rate
- Clinical trial risk
- Limited commercialization experience
Opportunities
- Expansion of mavorixafor into additional indications
- Potential partnerships with larger pharmaceutical companies
- Acquisition or licensing of new assets
- Positive clinical trial results
Threats
- Clinical trial failure
- Regulatory delays or rejection
- Competition from other therapies
- Financing risk
Competitors and Market Share
Key Competitors
- SAN
- BMY
- REGN
Competitive Landscape
X4's competitive advantages are its novel CXCR4 antagonist platform and focus on rare diseases. Disadvantages include its limited financial resources and reliance on a single product candidate.
Growth Trajectory and Initiatives
Historical Growth: Growth is contingent on the successful development and commercialization of mavorixafor.
Future Projections: Future projections are based on analyst estimates, which factor in clinical trial outcomes and market penetration.
Recent Initiatives: Focus is on advancing mavorixafor through clinical trials and preparing for potential commercialization.
Summary
X4 Pharmaceuticals is a clinical-stage biopharmaceutical company with a focus on developing therapies for rare diseases. It holds promise with its lead drug candidate, mavorixafor; however, the company faces the risks inherent in drug development and a need for further funding. Successful clinical trial outcomes and regulatory approvals will be crucial for its long-term success. It's financial metrics need to be watched closely. The market is competitive with larger pharmaceuticals, and thus partnerships would be beneficial.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC filings
- Company website
- Analyst reports
- Industry publications
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About X4 Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2017-11-16 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 143 | Website https://www.x4pharma.com |
Full time employees 143 | Website https://www.x4pharma.com |
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company also develops mavorixafor that is in Phase 3 4WARD clinical trial to evaluate the efficacy, safety, and tolerability of oral, once-daily mavorixafor with or without stable doses of G-CSF in people with congenital, acquired primary autoimmune, or idiopathic CN who are experiencing recurrent and/or serious infections. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications; and with Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand. The company is headquartered in Boston, Massachusetts.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.